ALIROCUMAB
Information current as at: 1 May 2025
The pharmaceutical company has withdrawn their submission for this medicine prior to the medicine being considered at the PBAC meeting.
PBAC meeting date: November 2022
Submission Details
- Brand name:
-
- Praluent®
- Pharmaceutical company:
- SANOFI-AVENTIS AUSTRALIA PTY LTD
- Condition/indication:
(therapeutic use) -
- Hypercholesterolaemia
- PBAC Submission type:
- Change to PBS listing (–)
- Comment:
- --
- Related medicines:
- --
Progress Details
-
Submission received for: - November 2022 PBAC meeting
-
Opportunity for consumer comment: - Open 27/07/2022 and close 21/09/2022 (see PBS Website)
-
PBAC meeting: - Not applicable
-
PBAC outcome published: - Not Applicable (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a576
Page last updated: 02 May 2024